Can nonliving nasal vaccines be made to work?

Reference

• Brandtzaeg P, Farstad IN, Johansen F-E, Morton HC, Norderhaug IN, Yamanaka T. The B-cell system of human mucosa and exocrine glands. Immunol. Rev. 171, 45–87 (1999).
   Google Scholar
• Rappuoli R, Pizza M, Douce G, Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today20, 493–500 (1999).
   PubMedGoogle Scholar
• Rask C, Fredriksson M, Lindblad M, Czerkinsky C, Holmgren J. Mucosal and systemic antibody responses after peroral or intranasal immunization: effects of conjugation to enterotoxin B subunits and/ or of coadministration with free toxin as adjuvant. APMIS108,178–186 (2000).
   PubMed Web of Science ®Google Scholar
• Cong Y, Oliver AO, Elson CO. Effects of cholera toxin on macrophage production of co-stimulatory cytokines. Eur. j Immunol. 31,64–71 (2001).
   Google Scholar
• Lycke N, Schön K. The B-cell targeted adjuvant, CTAl-DD, exhibits potent mucosal immunoenhancing activity despite pre-existing antitoxin immunity. Vaccine 19, 2542–2548 (2001).
   PubMed Web of Science ®Google Scholar
• Loon FPL van, Clemens JD, Chakraborty J et al. Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine 14,162–166 (1996).
   PubMed Web of Science ®Google Scholar
• Neutra MR, Frey A, Kraehenbuhl J-P. Epithelial M cells: gateways for mucosal infection and immunization. Ce1186,345–348 (1996).
   Google Scholar
• Baumann E, Binder BR, Falk W, Huber EG, Kurz R, Rosanelli K. Development and clinical use of an oral heat-inactivated whole cell pertussis vaccine. Develop. Biol. Stand 61,511–516 (1985).
   PubMedGoogle Scholar
• Jensen C. Active immunization against diphtheria by the combined subcutaneous and intranasal method. Proc. Royal Soc. Med. 30,1117–1148 (1937).
   PubMedGoogle Scholar
• Quilligan JJ Jr, Francis T Jr. Serological response to intranasal administration of inactive influenza virus in children. J. Clin. Invest. 26,1079–1087 (1947).
   PubMed Web of Science ®Google Scholar
• Oh Y, Ohta K, Kuno-Sakai H, Kim D, Kimura M. Local and systemic influenza haemagglutinin-specific antibody responses following aerosol and subcutaneous administration of inactivated split influenza vaccine. Vaccine 10,506–511 (1992).
   Google Scholar
• Greenbaum E, Furst A, Kiderman A et al Mucosa' [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine. Vaccine 20,1232–1239 (2002).
   PubMed Web of Science ®Google Scholar
• Samdal HH, Berstad AKH, Oftung F et al An inactivated whole-virus influenza vaccine given intranasally induced protective levels of serum antibodies in humans. Proceedings of The Fourth Annual Conference on Vaccine Research, Arlington, VA, USA, April 2001, S33 (2001).
   Google Scholar
• Haneberg B, Dalseg R, Wedege E et al Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect. Immun. 66,1334–1341 (1998).
   PubMed Web of Science ®Google Scholar
• Drabick JJ, Brandt BL, Moran EE, Saunders NB, Shoemaker DR, Zollinger WD. Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers. Vaccine 18,160–172 (2000).
   Web of Science ®Google Scholar
• Thomas G. Respiratory and humoral immune response to aerosol and intramuscular pertussis vaccine. j Hyg. (Camb) 74,233–237 (1975).
   PubMedGoogle Scholar
• Berstad AKH, Holst J, Froholm LO et al. A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers. Med. Microbiol 49,157–163 (2000).
   PubMed Web of Science ®Google Scholar
• Berstad AKH, Oftung F, Korsvold GE et al Induction of antigen-specific T-cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine. Vaccine 18,2323–2330 (2000).
   PubMed Web of Science ®Google Scholar
• Oftung F, Nwss LM, Wetzler LM et al. Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine. Infect. Immun. 67,921–927 (1999).
   PubMed Web of Science ®Google Scholar
• Hashigucci K, Ogawa H, Ishidate T et al Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine 14,113–119 (1996).
   PubMedGoogle Scholar
• Glueck R. Review of intranasal influenza vaccine. Adv. Drug Delivery Rev 51,203–211 (2001).
   PubMed Web of Science ®Google Scholar
• Bourguignon P, Bisteau M, Abarca J et al Reactogenicity in the nose and the brain of enterotoxins administered intranasally to mice. Proceedings of Molecular Approaches to Vaccine Design, Cold Spring Harbor, NY, USA, December 1999,23 (1999).
   Google Scholar
• Ginkel FW van, Jackson RJ, Yuki McGhee, Y. JR . Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. j Immunol 165,4778–4782 (2000).
   PubMed Web of Science ®Google Scholar
• Sun J-B, Holmgren J, Czerkinsky C. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc. Natl Acad. Sci. USA 91, 10795–10799 (1994).
   Google Scholar
• Dalseg R, Holst J, Tangen T et al. Outer membrane vesicles from Group B meningococci can act as mucosal adjuvant for influenza virus antigens. In: Vaccines 96: Molecular Approaches to the Control of Infectious Diseases. Brown F, Norrby E, Burton D, Mekalanos J (Eds), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 177–182 (1996).
   Google Scholar
• Berstad AKH, Andersen SR, Dalseg R et al. Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine. Vaccine 18,1910–1919 (2000).
   PubMed Web of Science ®Google Scholar
• Zollinger WD, Mandrell RE, McLeod Griffiss J. Enhancement of immunologic activity by noncovalent complexing of meningococcal group B polysaccharide and outer membrane proteins. In: Seminars in Infectious Disease (Vol. 4). Bacterial Vaccines. Robbins JB, Hill JC, Sadoff JC (Eds), Thieme-Stratton Inc., New York, NY, USA, 254–262 (1980).
   Google Scholar
• On N, Robin G, Cohen D, Arnon R, Lowell GH. Immunogenicity and efficacy of oral or intranasal Shigella ilexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect. Immun. 61, 2390–2395 (1993).
   Google Scholar
• Fries LF, Montemarano AD, Mallett CP, Taylor DN, Hale TL, Lowell GH. Safety and immunogenicity of a proteosome—Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect. Immun. 69,4545-4553 (2001).
   Google Scholar
• Haugan A, Wold N, Dao PXT et al Bordetella pertussis may act as adjuvant as well as inhibitor of immune responses to nasal vaccines. Proceedings of The Fourth Annual Conference on Vaccine Research, Arlington, VA, USA, April 2001, S35 (2001).
   Google Scholar
• Wu H-Y, Russell MW Comparison of systemic and mucosal priming for mucosal immune responses to a bacterial protein antigen given with or coupled to cholera toxin (CT) B subunit and effects of pre-existing anti-CT immunity. Vaccine 12, 215–222 (1994).
   PubMed Web of Science ®Google Scholar
• Bergquist C, Lagergard T, Holmgren J. Anticarrier immunity suppresses the antibody response to polysaccharide antigens after intranasal immunization with the polysaccharide—protein conjugate. Infect. Immun. 65,1579–1583 (1997).
   Google Scholar
• Boyce TG, Hsu HH, Sannella EC et al Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 19,217–226 (2001).
   Web of Science ®Google Scholar
• Hu K-F, Löygren-Bengtsson K, Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv. Drug Delivery Rev 51,149–159 (2001).
   PubMed Web of Science ®Google Scholar
• Jabbal-Gill I, Lin W, Kistner O, Davis SS, Illum L. Polymeric lamellar substrate particles for intranasal vaccination. Adv Drug Delivery Rev 51,97–111 (2001).
   PubMed Web of Science ®Google Scholar
• McNeela EA, Mills KHG. Manipulating the immune system: humoral versus cell-mediated immunity. Adv. Drug Delivery Rev 51,43–54 (2001).
   PubMed Web of Science ®Google Scholar
• Singh M, Briones M, O'Hagan DT. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. j Control Release 70,267–276 (2001).
   Google Scholar
• Bakke H, Setek TN, Haugen IL, Holst J, Aaberge IS, Haneberg B. The immunological memory and boosting of IgA antibodies in secretions induced by a nonreplicating nasal vaccine have different kinetics from those of IgG antibodies in serum, Proceedings of The Third Annual Conference on Vaccine Research, Washington DC, USA, April-May 2000, 63 (2000).
   Google Scholar
• Illum L, Jabbal-Gill I, Hinchcliffe M, Fischer AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Delivery Rev 51,81–96 (2001).
   PubMed Web of Science ®Google Scholar
• Gizurarson S, Aggerbeck H, Gudbrandsson FK, Valdirnarsson H, Heron I. Intranasal vaccination against diphtheria and tetanus in human subjects. Vaccine Res. 6,41–47 (1997).
   Google Scholar
• Aggerbeck H, Gizurarson S, Wantzin J, Heron I. Intranasal booster vaccination against diphtheria and tetanus in man. Vaccine 15,307–316 (1997).
   PubMed Web of Science ®Google Scholar
• Katial RK, Brandt BL, Moran EE, Marks S, Agnello V, Zollinger WD. Immunogenicity and safety testing of group B intranasal meningococcal native outer membrane vesicle vaccine. Infect. Immun. 70,702–707 (2002).
   PubMed Web of Science ®Google Scholar
• Fischer M, Holst J, Aaberge IS et al. Immunogenicity of an intranasal Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults. Proceedings of the Twelfth International Pathogenic Neis,seria Conference, Galveston, Texas, USA, November 2000,45 (2001).
   Google Scholar
• Bakke H, Lie K, Haugen IL et al. Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance. Infect. Immun. 69,5010–5015 (2001).
   PubMed Web of Science ®Google Scholar
• Hvalbye BKR, Aaberge IS, Lovik M, Haneberg B. Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection. Infect. Immun. 67, 4320–4325 (1999).
   PubMed Web of Science ®Google Scholar
• Janakova L, Bakke H, Haugen IL et al. Influence of intravenous anesthesia on mucosal and systemic antibody responses to nasal vaccines. Infect. Immunol (In Press 2002).
   Google Scholar
• Saunders NB, Shoemaker DR, Brandt BL, Moran EE, Larsen T, Zollinger WD. Immunogenicity of intranasally administered meningococcal outer membrane vesicles in mice. Infect. Immun. 67,113–119 (1999).
   PubMed Web of Science ®Google Scholar